Beleggers reageren ijskoud op de langetermijnplannen. Novo moet zich haasten om het naderende patentverlies van Ozempic en Wegovy in 2032 op te vangen.
The Danish company seeks to convince investors it can compete in an increasingly crowded f...
Novo shares fell as much as 7% on Monday after the company laid out new growth ambitions t...